# Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea

> **NCT05150587** · PHASE2 · COMPLETED · sponsor: **Alfasigma S.p.A.** · enrollment: 216 (actual)

## Conditions studied

- Papulopustular Rosacea

## Interventions

- **DRUG:** Rifaximin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05150587
- **Lead sponsor:** Alfasigma S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-05
- **Primary completion:** 2022-10-20
- **Final completion:** 2022-10-20
- **Target enrollment:** 216 (ACTUAL)
- **Last updated:** 2024-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05150587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05150587, "Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05150587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*